文献速递急性肾损伤血液净化与透析

预测新生儿和婴儿连续性肾脏替代治疗的死亡率和短期结局

Predicting mortality and short-term outcomes of continuous kidney replacement therapies in neonates and infants.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

基于EurAKId登记研究中95例接受连续性肾脏替代治疗(CKRT)的新生儿和婴儿,使用XGBoost模型分析死亡和出院时蛋白尿的预测因素。总体死亡率为47.3%,新生儿与婴儿间无显著差异。CKRT开始时尿量较低、血肌酐升高幅度较大、开始透析时间较长和血压较低与死亡风险增加相关;出院时30.6%的存活者存在蛋白尿,入院时和CKRT开始时较高的血肌酐浓度以及原发肾脏病是蛋白尿最重要的危险因素。

要点

  • 总体死亡率为47.3%,新生儿与婴儿间无显著差异(53.3% vs 44.4%,P=0.422)。
  • CKRT开始时尿量较低、血肌酐升高幅度较大、开始透析时间较长和血压较低与死亡风险增加相关。
  • 出院时30.6%的存活者存在蛋白尿,入院时和CKRT开始时较高的血肌酐浓度及原发肾脏病是重要危险因素。

核心结论

  • 作者提出XGBoost模型用于识别新生儿和婴儿CKRT短期结局的相关因素。
  • CKRT开始时尿量较低、急性肾损伤进展更严重和开始CKRT时间较长可能是新生儿和婴儿死亡的重要危险因素。
  • 原发肾脏病及相关生化参数是出院时蛋白尿的强预测因素。

研究设计与样本

  • 研究纳入EurAKId登记研究(NCT02960867)中接受CKRT治疗的新生儿和婴儿,共95例。
  • 使用人工智能XGBoost模型识别与短期结局(出院前死亡和出院时蛋白尿)相关的关键临床因素。
  • 考虑的因素包括患者临床特征、人体测量学特征和CKRT技术设置。

主要发现

  • 95例患者中新生儿占31.6%,婴儿占68.4%,入院时中位年龄为1个月(四分位距IQR 0-7个月),10例为早产儿。
  • 总体死亡率为47.3%,新生儿与婴儿间无显著差异(53.3% vs 44.4%,P=0.422)。
  • 预测死亡率的XGBoost模型准确度为59.53%±0.96%,AUC为0.64±0.11。
  • 出院时30.6%的存活者存在蛋白尿;预测蛋白尿的XGBoost模型准确度为79.11%±2.46%,AUC为0.74±0.04。
  • CKRT开始时尿量较低、血肌酐升高幅度较大、开始透析时间较长和血压较低与死亡风险增加相关;入院时和CKRT开始时较高的血肌酐浓度以及原发肾脏病是蛋白尿最重要的危险因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Continuous kidney replacement therapy (CKRT) has emerged as a valuable treatment option in critically ill neonates and infants with acute kidney injury (AKI) requiring dialysis. In this population, we apply artificial intelligence (AI) to identify factors influencing mortality and short-term adverse kidney outcomes. METHODS: The study involved neonates and infants included in the EurAKId Registry (NCT02960867), who underwent CKRT treatment. Using the AI XGBoost models, we identified key clinical factors associated with short-term outcomes: mortality before hospital discharge, as well as proteinuria at discharge. We considered the patients' clinical characteristics, anthropometric features, and CKRT technical settings. RESULTS: The study comprised 95 patients: 31.6% neonates and 68.4% infants with a median age at hospital admission of 1 month (interquartile range, IQR 0-7 months). Ten children were born prematurely. The overall mortality rate was 47.3% and did not differ significantly between neonates and infants (53.3% vs 44.4%, respectively, P = .422). The XGBoost model for predicting mortality had the accuracy of 59.53% ± 0.96% and AUC of 0.64 ± 0.11. Lower urine output at CKRT initiation, a greater rise in serum creatinine (SCr), longer time to dialysis initiation, and lower blood pressure were associated with increased risk of mortality. Proteinuria at hospital discharge was present in 30.6% of survivors. The XGBoost model for predicting proteinuria had the accuracy of 79.11% ± 2.46% and AUC (0.74 ± 0.04). Higher SCr concentrations at hospital admission and at CKRT start, as well as primary kidney disease were the most important risk factors for proteinuria. CONCLUSION: We propose the XGBoost models for identifying factors associated with short-term outcomes of CKRT in neonates and infants. Lower urine output at CKRT start, more severe AKI progression and longer time to CKRT initiation might be important risk factors for mortality in infants and neonates. Primary kidney disease and related biochemical parameters are strong predictors of proteinuria at hospital discharge.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Deja A, Deja K, Cappoli A, et al. Predicting mortality and short-term outcomes of continuous kidney replacement therapies in neonates and infants. Nephrol Dial Transplant. 2026. PMID: 40862677. doi:10.1093/ndt/gfaf173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。